PTH and hyperparathyroidism: Compared with the J-DAVID cohort, participants in the Morrone et al. trial had a higher prevalence of cardiovascular disease (52.5% versus 25%), more severe hyperparathyroidism (baseline median serum PTH 240 vs 85.6 pg/mL) and shorter dialysis vintage (mean 2.9 vs 5.5 years).